— Know what they know.
Not Investment Advice
Also trades as: KLTOW (NASDAQ) · $vol 0M

KLTO NASDAQ

Klotho Neurosciences, Inc.
1W: -19.0% 1M: +75.0% 3M: -10.0% YTD: +19.4% 1Y: +36.3%
$0.38
Last traded 2026-03-16 — delisted
NASDAQ · Healthcare · Biotechnology · $20.1M mcap · 40M float · 8.03% daily turnover · Short 59% of daily vol
Smart Money Score
Watch 25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$20.1M
52W Range0.114-3.91
Volume95,000
Avg Volume3,231,766
Beta2.23
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOJoseph A. Sinkule
Employees3
SectorHealthcare
IndustryBiotechnology
IPO Date2022-04-29
13576 Walnut Street
Omaha, NE 68144
US
833 931 6330
About Klotho Neurosciences, Inc.

Klotho Neurosciences, Inc. operates as a biopharmaceutical enterprise focused on devising medical treatments for various conditions, including cancer, cardiovascular ailments, and neurodegenerative disorders. Their leading gene therapy assets encompass AMI-101, which is designed for the management or prevention of Alzheimer's disease, and AMI-202, aimed at treating or averting amyotrophic lateral sclerosis. Formerly known as Anew Medical, Inc., the company underwent a name change to Klotho Neurosciences, Inc. in September 2024. The firm's main office is situated in Omaha, Nebraska.

Recent Insider Trades

NameTypeSharesPriceDate
LeBlanc Jeff A-Award 2,500,000 — 2026-03-04
El-Dada Riad Hussein A-Award 350,000 — 2026-03-04
ZENTMAN SAMUEL M A-Award 350,000 — 2026-03-04
Hirschman Shalom A-Award 350,000 — 2026-03-04
McGarity Jon A-Award 350,000 — 2026-03-04

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms